Abstract. There are several scientific approaches for the determination of cellular growth influences of known or novel substances under in vitro conditions, among which colourimetric absorption measurement is considered to be one of the convenient methods. [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay is one of the commonly used colourimetric absorption assays based on the ability of dehydrogenase from viable cells to produce the brown soluble formazan detectable at 490 nm. Here we have tested the possible growth influence of iron (II) sulphate on two human cancer cell lines, the K562 chronic myelogenous leukaemia and T47D breast carcinoma cells, based on the MTS assay. We found that iron (II) sulphate possessed an inhibitory effect when added at 16-to 125-μM concentrations, but iron (II) sulphate became growth stimulatory when its concentration was further increased to 1000 μM. In addition, a dosedependent increase in absorbance at the same wavelength was observed when we repeated the experiments without the addition of MTS and phenazine methosulfate. When we further repeated the cell growth determinations using adenosine triphosphate content assay for K562 and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for T47D, iron (II) sulphate showed a consistent dosedependent growth inhibitory effect. Morphological investigation after methylene blue staining clearly demonstrated that iron (II) sulphate, at a concentration of 1000 μM, is cytotoxic to T47D cells. Interestingly, a consistent increment for the absorbance at 490 nm was further observed with increased iron (II) sulphate concentration either in the presence or absence of MTS even in a cell-free environment. Thus we conclude that iron (II) sulphate is actually growth inhibitory and even cytotoxic at high concentrations towards the K562 and T47D cancer cells and the paradoxical proliferative activity of iron (II) sulphate on these two cancer cell lines using the MTS assay was solely due to the oxidation of initial pale green iron (II) to brownish iron (III) during incubation in the aqueous condition.
Introduction
High throughput current drug discovery depends on massive screening of chemical libraries against both extra-and intracellular molecular targets, to identify compounds with desired biological activities (1) . In respect to experimental therapeutic cancer research, there are several methodologies that could be employed for the identification of cytotoxic activities, among which colourimetric absorbance assay studies are cheap, simple and convenient strategies, when compared (9) . Itoh et al showed that 100 μM iron ions were sufficient to induce cell death, after 3 h of treatment, in murine hepatoma cells, but not in normal murine hepatocytes.
Here we have performed experiments to evaluate the possible antiproliferative activity of iron (II) sulphate on human cancer cell lines, employing three different biochemical methods, combining these with cellular morphology assays. Different results were observed using the employed different approaches.
Materials and methods
Cell lines and cell culture conditions. The human chronic myelogenous leukaemia cell line K562 (CCL-243) and the human breast carcinoma T47D (HTB-133) cell line were obtained from American Type of Culture Collection. Cells were maintained in minimum essential medium (Sigma Chemicals) supplemented with 10% heat inactivated fetal bovine serum (Invitrogen), together with antibiotics including penicillin and streptomycin. Cells were allowed to grow in a humidified cell culture incubator in 5% carbon dioxide. Iron (II) sulphate stock solution was prepared freshly each time at a concentration of 1 M by dissolving in sterile distilled water and at least a 1000-fold dilution was used in the cell culture experiment.
MTS assay. Changes in the cellular viability of iron (II)
sulphate-treated cells were monitored using the MTS activity assay as reported previously (2-5). Briefly, both K562 CML cells and T47D breast carcinoma cells at a concentration of 1x10 5 per ml were seeded at day 0. After 24 h, medium without phenol (as phenol red would interfere with development of the brownish colour from the reduced MTS) was changed and freshly prepared iron (II) sulphate was added at different concentrations. After 48 h of incubation, MTS (Promega)/ PMS (Sigma) as electron coupling agent mixed solution was added directly into the wells and further incubated for brown colour development. Afterwards, optical absorbance was determined at 490 nm using a microplate reader according to the user manual.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Briefly, MTT assay was performed similarly to the MTS assay described before. The major difference was that after incubating MTT (5 mg/ml dissolved in phosphate buffered saline, both from Sigma) with T47D cancer cells, cell culture medium was removed from the wells and dimethyl sulfoxide (Sigma) was added instead of a direct reading of the culture plate after adding the MTS/PMS, as mentioned previously. Finally, absorbance was determined at 595 nm using a microplate reader.
Adenosine triphosphate (ATP) determination. Briefly, the methodology for determination of ATP content as a measurement of cellular growth was the same as described elsewhere (10). Here we used an ATP quantitation kit purchased from Promega. The resulting ATP content was determined by chemiluminescence detection using a microplate reader.
Morphological monitoring of iron (II) sulphate-treated T47D
cells. Any morphological changes associated with iron (II) sulphate treatment of T47D breast cancer cells were recorded under an inverted microscope at the scheduled time points after fixing the cells with ethanol and staining with methylene blue.
Statistical analysis. Student's t-test was used in data analysis, and the results were considered as statistically significant when p values were <0.05 when treated samples were compared with untreated controls. 
Results

Iron (II) sulphate showed an inhibitory and then a proliferative effect on both K562 and T47D cancer cells after MTS assay.
We have determined that Fe (II) sulphate appears to exhibit both growth inhibitory as well as growth stimulatory effects on the two human cancer cell lines, K562 and T47D, when the test is based on the MTS assay and 48-h incubations are performed at concentrations ranging from 16-1000 μM. The results obtained are shown in Fig. 1A and B. We found that iron (II) sulphate exhibits an inhibitory effect when used at 16-to 125-μM concentrations. On the contrary, iron (II) sulphate appeared to be growth stimulatory when its concentration was further increased to 1000 μM, and the MTS assays were performed. In addition, we also determined the optical absorbance at 490 nm after iron (II) sulphate incubation for 48 h but before MTS/PMS addition; interestingly, a dosedependent increment was also observed as shown in Fig. 1A and B, suggesting that the cell treatment might strongly interfere with optical absorbance at 490 nm.
Iron (II) sulphate showed a consistent growth inhibitory effect on K562 CML cells and T47D breast cancer cells when examined by ATP content assay and MTT assay respectively.
We repeated the iron (II) sulphate incubation experiment on K562 CML cells and monitored the effects by using the ATP content assay. The results obtained are shown in Fig. 2A . Surprisingly, but in agreement with the MTS assay performed on cells treated with 16-to 125-μM concentrations, a dosedependent growth inhibitory effect with increasing iron (II) sulphate concentration was observed.
In order to confirm these data, we further repeated the iron (II) sulphate experiment on T47D breast cancer cells and performed an MTT assay. Results are shown in Fig. 2B , demonstrating an even stronger dose-dependent anti-proliferative effect with increasing iron (II) sulphate concentration.
A consistent increment of absorbance at 490 nm was observed with increased iron (II) sulphate concentration either in the absence or presence of MTS/PMS reagents even in a cell-free environment.
Since the different assay methods employed showed controversial results, we determined whether the growth-stimulatory effect of iron (II) sulphate, when used at a high concentration and assayed by MST/PMS test, was actually a false positive phenomenon. To this aim, we repeated the experiment again to see if there was any influence of iron (II) sulphate in a cell-free environment, in the presence or absence of MTS/PMS. Fig. 3 shows that there was a consistent increment of the absorbance at 490 nm observed with increased iron (II) sulphate concentration, either in the presence or absence of MTS/PMS reagents, even in a cell-free environment.
Iron (II) sulphate was actually cytotoxic when administered to T47D breast cancer cells at a 1000-μM concentration. The morphological changes of T47D breast cancer cells treated with 1000-μM iron (II) sulphate for 48 h were investigated under an inverted microscope after fixing the cells with ethanol and staining with methylene blue. Fig. 4 clearly shows that iron (II) sulphate is cytotoxic towards T47D cancer cells at a high concentration (1000 μM) as loss of adherent property, cell rounding and shrinkage were observed. 
Discussion
It is well known that many transitional metal ions are cytotoxic towards human cancer cells. Examples include vanadium, chromium and iron. When concerning vanadium, Lampronti et al discovered that vanadium (V) and (IV) complexes including NaVO 3 2 .H 2 O were all antiproliferative towards K562 CML cells, when administered for 96 h at concentrations ranging from 15-1500 μM. Inhibition of K562 cell growth was not associated with erythroid differentiation, but with activation of apoptosis (8) . In considering chromium, it was found that chromium (VI) could readily induce oxidative stress, lipid oxidation, nucleic damage and programmed cell death in both in vitro and in vivo models including K562 CML and murine macrophage A774A.1 cells as well as an experimental mouse model system (11) . In these experiments concentrations ranging from 0.6 μM and 25 μM where used in 48-h treatments. Even chromium (VI) was shown to have stronger toxic effect when compared with chromium (III), perhaps the safety of chromium (III) was mainly due to the nature of its corresponding ligands. Iron (II) is also reported to have cytotoxic activity on murine hepatoma but not normal murine hepatocytes. The mitochondrial DNA was markedly damaged after incubating with iron (II) at a concentration of 100 μM for 3 h. It was believed that the major mechanism was the lower level of superoxidase dismutase in rat hepatoma cells when compared with nontransformed cells. Therefore it is believed that iron (II) at a high concentration is cytotoxic towards cancer cells (9) .
Here we have performed experiments to evaluate whether iron (II) sulphate is a true anti-proliferative and cytotoxic agent on human cancer cell lines, after comparison of three different biochemic methods as well as cellular morphology determinations. We used as experimental models two human cancer cell lines, the CML K562 and the breast carcinoma T47D cell lines.
We first analysed the possible growth inhibitory effects of iron (II) sulphate on these two cancer cell lines by the MTS assay. We found that iron (II) sulphate exhibits an inhibitory effect when used at concentrations ranging between 16 and 125 μM; on the contrary, iron (II) sulphate became surprisingly growth stimulatory when its concentration was further increased to 1000 μM. In addition, a dose-dependent increase in absorbance was observed when we repeated the experiments at the same wavelength without the addition of MTS/PMS. This suggested that the increase in absorbance in the presence of high concentrations (1000 μM) of iron (II) sulphate might not be due to the redox reaction between the cellular dehydrogenase and MTS/PMS. When we further repeated the assay using adenosine triphosphate content detection and MTT assay, iron (II) sulphate showed a consistent dose-dependent growth inhibitory effect on both K562 and T47D cells. Therefore, the conclusion that iron (II) sulphate is growth stimulatory on both cancer cell lines at higher concentrations is unlikely. When we performed morphological investigation after methylene blue staining, there was a clear demonstration that iron (II) sulphate at a concentration of 1000 μM is cytotoxic to T47D cells. In the case of K562 CML cells, we also observed a certain degree of cell shrinkage but it was not as evident as in T47D (data not shown). Finally, a consistent increment of the absorbance at 490 nm was observed with increased iron (II) sulphate concentration in a cell-free environment, either in the presence or in the absence of MTS/PMS. Thus we believe that iron (II) sulphate is actually growth inhibitory and cytotoxic at high concentrations towards both K562 and T47D cancer cell lines. The paradoxical growth stimulating activity found only using the MTS assay was solely due to the oxidation of initial pale green iron (II) to brownish iron (III) at the highest concentrations used during incubation in the aqueous condition; accordingly with our interpretation, the change in colour of the iron (III) ion form during the continuous oxidation of iron (II) was responsible for the masking of the decrease in brown colour originally contributed by the low-level cellular metabolic activity. Such misinterpretation could easily be avoided if the original culture medium is removed before the addition of MTS/PMS. Therefore, it is suggested that special precautions should be taken when studying growth stimulatory or growth inhibitory assays using MTS/PMS if medium is not removed before the addition of the MTS/PMS reagents.
It is widely accepted that there is an urgent need for novel therapeutic agents for cancer treatment and in vitro screening is the first step to select potential candidates for further investigations. However, in vitro drug screening may not be as simple as expected as mentioned by Etique et al when ethanol was used as a solvent for experimental therapeutic research when MCF-7 breast cancer cells were employed as the experimental tool (12) . In conclusion, basic fundamental chemistry knowledge is an essential and necessary criterion for those who are working in the field of drug discovery and development.
